| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
|
Medicine details |
|
| Medicine name | bevacizumab (Avastin®) |
| Formulation | 25 mg/ml concentrate for solution for infusion |
| Reference number | 696 |
| Indication | In combination with carboplatin and paclitaxel for front-line treatment of advanced (FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/06/2012 |
| NICE guidance | |